BioTrace Medical is closing in on its $3.5 million goal, having raised $3.4 million in a funding round, according to a regulatory filing.
BioTrace, which is backed by early-stage medtech angel Xandex Investments, is developing a temporary cardiac pacing device to treat reversible symptomatic bradycardia.
San Mateo, Calif.-based BioTrace counts medical device legend Dr. Thomas Fogarty, inventor of the embolectomy catheter, as a member of its board, according to a regulatory filing.
BioTrace raised more than $3.4 million in the equity round from 6 unnamed investors, according to the filing.
At DeviceTalks Boston, Tyler Shultz will give attendees an inside look at Theranos and how he was able to sound the alarm after he realized the company was falling apart. Shultz will take attendees behind the story that everyone is talking about: the rise and fall of Elizabeth Holmes and her diagnostic company, Theranos.
Join Shultz and 1,000+ medical device professionals at the 8th annual DeviceTalks Boston.